Psyence Biomedical Ltd. has announced an agreement with Psyence Labs Ltd. for a transaction involving the issuance and purchase of shares. According to the details disclosed, Psyence Biomed II Corp., a subscriber, will acquire 1,750 subscription shares at a price of US$2000. The transaction aims to further the business activities of Psyence Labs, which includes psychedelic cultivation and extraction based in Southern Africa, along with the export of raw materials to various partners for the development of pharmaceutical-grade psychedelic substances. The agreement was signed on August 15, 2025, in Toronto, with Jody Aufrichtig, Chairman of the Board, representing the subscriber.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-085011), on September 05, 2025, and is solely responsible for the information contained therein.